Materia Medica Malaysiana

ChondroGene Enters into Clinical Collaborations with Two Malaysian Hospitals

ChondroGene Limited (TSX Venture: CDG) announced
today that it has entered into clinical collaborations with Lam Wah EE
Hospital and Island Hospital, two leading hospitals in Penang, Malaysia.
"These are two of the most prestigious hospitals in Malaysia and South
East Asia," stated Malaysian-born Dr. C.C. Liew, Chief Scientific Officer of
ChondroGene. "Malaysia has extremely modern healthcare facilities staffed with
many North American and European trained physicians and researchers.
Initially, these hospitals will be a key source of genetically diverse
clinical samples in a variety of disease areas. Eventually, they will offer
their patients ChondroGene's molecular diagnostic tests and services based on
the Sentinel Principle."
The hospitals will begin collecting blood samples from consenting
patients in disease areas that coincide with ChondroGene's primary areas of
interest - cancer, cardiovascular disease, central nervous system disorders
and arthritis. The information from these samples will provide additional data
useful in identifying blood-based biomarkers for specific diseases. The data
will also be added to ChondroGene's growing database of gene expression
profiles which currently contains profiles from several thousand people
possessing a wide range of disease conditions, as well as from normal
patients. The hospitals have also agreed to offer ChondroGene's molecular
tests to their patients, as these tests become available.
"We are pleased to be working with these two key hospitals in the
region," stated K. Wayne Marshall, President and CEO of ChondroGene. "We
expect to enter into similar relationships with other organizations around the
world in the future in order to further expand the genetic diversity of our
gene expression database as we move towards developing commercial products."